Paper Details

  1. Home
  2. Paper Details

Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.

Author: CracowskiJean-Luc, HumbertMarc, KhouriCharles, LepelleyMarion, MontastrucFrançois, RoustitMatthieu

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review compares the safety profiles of sildenafil, tadalafil, and riociguat in pulmonary hypertension. These medications are commonly used to treat pulmonary hypertension, and the review highlights important considerations for clinicians when choosing among these treatment options.
Paper Details　
Original Abstract of the Article :
Recent guidelines recommend riociguat, a soluble guanylate cyclase (sGC) stimulator, and the type 5 phosphodiesterase inhibitor (PDE5i) tadalafil or sildenafil as treatments for pulmonary arterial hypertension. We compared the safety profiles of sildenafil, tadalafil, and riociguat in pulmonary hype...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.chest.2017.12.008

データ提供：米国国立医学図書館（NLM）

Comparing the Safety Profiles of Drugs for Pulmonary Hypertension

Pulmonary hypertension (PH) is a serious condition characterized by high blood pressure in the arteries of the lungs. This condition can lead to heart failure and other complications. While there have been significant advances in treating PH, it is important to ensure that the treatments themselves are safe and effective.

This research investigated the safety profiles of three commonly prescribed medications for PH: riociguat, tadalafil, and sildenafil. Riociguat is a soluble guanylate cyclase (sGC) stimulator, while tadalafil and sildenafil are type 5 phosphodiesterase inhibitors (PDE5i). These drugs all work by relaxing the blood vessels in the lungs, which helps to lower blood pressure.

The study compared the safety profiles of these drugs by analyzing data from clinical trials and a large pharmacovigilance database. This approach allowed researchers to gain a comprehensive understanding of the potential side effects of these medications.

The Importance of Selecting Safe and Effective Treatments

When treating a serious condition like PH, it is essential to choose a medication that is both safe and effective. This research provides valuable information about the potential side effects of three commonly prescribed medications for PH. This knowledge can help clinicians make informed decisions about which medications are most appropriate for their patients.

Safe and Effective Treatment Options for Pulmonary Hypertension

This research highlights the importance of carefully considering the safety profiles of medications used to treat PH. It emphasizes the need for continued research and monitoring to ensure that patients receive the safest and most effective treatments. Understanding the potential risks and benefits of various medications is crucial for making informed decisions about our health.

Dr.Camel's Conclusion

This research reminds us that even the most promising treatments can have side effects. It's like navigating a vast desert: we need to be aware of the potential dangers and choose our path wisely. This study provides valuable information that can help us make informed decisions about our health and well-being.

Date :
  1. Date Completed 2019-09-23
  2. Date Revised 2019-09-23
Further Info :

Pubmed ID

29275134

DOI: Digital Object Identifier

10.1016/j.chest.2017.12.008

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.